Evidence map›Paper›PMID 39762416›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2025

A universal gene expression signature-based strategy for the high-throughput discovery of anti-inflammatory drugs.

Juan Feng, Honglei Dang, Xiaoling Zhang, Wenting Huang, Chengmei Ma, Aixiang Zhang, Mimi Hao, Lan Xie

Abstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juan FengMedical Systems Biology Research Center, School of Medicine, Tsinghua University, Beijing, 100084, China.
Honglei DangBeijing CapitalBio Pharma Co., Ltd, Beijing, 102206, China.
Xiaoling ZhangNational Engineering Research Center for Beijing Biochip Technology, Beijing, 102206, China.
Wenting HuangMedical Systems Biology Research Center, School of Medicine, Tsinghua University, Beijing, 100084, China.
Chengmei MaNational Engineering Research Center for Beijing Biochip Technology, Beijing, 102206, China.
Aixiang ZhangNational Engineering Research Center for Beijing Biochip Technology, Beijing, 102206, China.
Mimi HaoNational Engineering Research Center for Beijing Biochip Technology, Beijing, 102206, China.
Lan XieMedical Systems Biology Research Center, School of Medicine, Tsinghua University, Beijing, 100084, China. xielan@tsinghua.edu.cn.

Funding

Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine NO. ZYYCXTD-D-202201National Natural Science Foundation of China NO. 82204759Shenzhen Science and Technology Program NO. RCBS20210609103650047
6 · The paper itself

Abstract

backgroundTraditional Chinese medicine (TCM) is a valuable resource for drug discovery and has demonstrated excellent efficacy in treating inflammatory diseases. This study aimed to develop a universal gene signature-based strategy for high-throughput discovery of anti-inflammatory drugs, especially Traditional Chinese medicine (TCM).

methodsThe disease gene signature of liposaccharide-stimulated THP-1 cells and drug gene signatures of 655 drug candidates were established via sequencing. Anti-inflammatory drugs were screened based on similarities between drug gene signatures and the reversed disease gene signature.

resultsThrough screening, 83 potential anti-inflammatory drugs were identified. The efficacy of the TCM formula Biyun Powder, along with individual TCMs, Centipedea Herba, Kaempferiae Rhizoma, and Schizonepetae Spica Carbonisata, was verified in vitro or in vivo. Mechanistically, they exerted anti-inflammatory effects by inhibiting the nuclear factor-kappa B pathway. Kaempferol and luteolin were identified as bioactive IκB kinase-β inhibitors in Kaempferiae Rhizoma and Schizonepetae Spica Carbonisata, respectively.

conclusionWe developed a universal gene signature-based approach for the high-throughput discovery of anti-inflammatory drugs that is applicable to compounds and to TCM herbs/formulae and established a workflow (screening, validation of efficacy, and identification of the mechanism of action and bioactive compounds) that can serve as a research template for high-throughput drug research.

Indexed as

Anti-Inflammatory AgentsDrugs, Chinese HerbalAnimalsDrug DiscoveryHigh-Throughput Screening AssaysHumansInflammationLipopolysaccharidesMaleMedicine, Chinese TraditionalMiceNF-kappa BTHP-1 CellsTranscriptomeAnti-Inflammatory AgentsDrugs, Chinese HerbalLipopolysaccharidesNF-kappa BAnti-inflammatory drug discoveryBiyun PowderCentipedea HerbaGene signatureKaempferiae RhizomaSchizonepetae Spica Carbonisata

Identifiers

PMID39762416
PMCPMC11703948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.